Products for Research Use Only
RegisterLogin

Difamilast

CAT: 0804-HY-109085-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109085-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM) . Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) [1][2][3].
CAS Number
937782-05-3
Product Name Alternative
OPA-15406
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/difamilast.html
Purity
99.40
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)OC(C=C(C1=NC(CNC(C(C=CC=C2)=C2OCC)=O)=CO1)C=C3)=C3OC(F)F
Molecular Formula
C23H24F2N2O5
Molecular Weight
446.44
References & Citations
[1]Hanifin JM, et, al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD) : A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016 Aug;75 (2) :297-305.|[2]Ahluwalia J, et, al. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017 Sep;77 (13) :1389-1397.|[3]Soeberdt M, et, al. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020 Aug 15;881:173242.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDE4

Alternative Products

CatalogName
T27172-01Difamilast
TMIH-0190-01Difamilast-d5

Popular Products